SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
A drug that could raise IQ - Balance Therapeutics raises $18M, conducting Down Syndrome trials
News | 03. 19. 2015
Balance Therapeutics
MedCity News, March 19, 2015 - Stanford spinout Balance Therapeutics just raised $18 million for its therapy that could raise the IQ of people with intellectual disability. It’s using a small molecule drug that has been around for decades – GABA-A antagonists – but rationalizes the approach by delving deeper into the molecular underpinnings of what causes diseases like Down Syndrome and dementia.
And it could improve the IQ of a person with Down Syndrome 10 to 20 percent.
